MOG (35-55), human
Based on 1 Customer Validation
MOG (35-55), human is a synthetic encephalitogenic peptide fragment (residues 35-55) of human myelin oligodendrocyte glycoprotein, and also serves as a myelin oligodendrocyte glycoprotein peptide epitope. MOG (35-55), human induces mild central nervous system inflammation in mice, but does not trigger demyelinating lesions, only causing mild clinical neurological symptoms. MOG (35-55) induces experimental autoimmune encephalomyelitis mouse models that recapitulate the features of optic neuritis, multiple sclerosis, myelin oligodendrocyte glycoprotein antibody-associated diseases, and neuromyelitis optica spectrum disorders.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.10%
- CAS No.: 163158-19-8
- Formule: C120H179N35O28S
- Masse moléculaire:2591.99
-
Stockage:
Sealed storage, away from moisture and light, under nitrogen.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
In Vivo
MOG (35-55) induces experimental autoimmune encephalomyelitis in mice, generating a persistent optic neuritis phenotype accompanied by acute visual loss, progressive retinal thinning, retinal ganglion cell loss, and short-segment optic nerve demyelination, which recapitulates the features of multiple sclerosis, myelin oligodendrocyte glycoprotein antibody-associated disease, and neuromyelitis optica spectrum disorders[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/Lt (female, 12-18 weeks of age, induced via intradermal injection of MOG (35-55), human emulsified in complete Freund's adjuvant, followed by intravenous pertussis toxin)[1]
-
Dosage:100 μg (MOG (35-55), human); 300 ng (pertussis toxin)
-
Administration:intradermal; single dose; emulsified in complete Freund's adjuvant, divided equally among hind footpads and neck; intravenous; two doses (immediately post-peptide injection and 48 hours later)
-
Result:Resulted in 50% clinical disease incidence (2/4 mice).
Resulted in 66.7% histological disease incidence (2/3 mice).
Delayed disease onset to day 14.
Revealed only a few foci of mild inflammation with no demyelination in the central nervous system.
-
Animal Model:C57BL/6 (female, 12-18 weeks of age, induced via intradermal injection of MOG (35-55), human emulsified in complete Freund's adjuvant, followed by intravenous pertussis toxin)[1]
-
Dosage:100 μg (MOG (35-55), human); 300 ng (pertussis toxin)
-
Administration:intradermal; single dose; emulsified in complete Freund's adjuvant, divided equally among hind footpads and neck; intravenous; two doses (immediately post-peptide injection and 48 hours later)
-
Result:Resulted in 20% clinical disease incidence (1/5 mice).
Resulted in 33.3% histological disease incidence (1/3 mice).
Delayed disease onset to day 13.
Revealed only a few foci of mild inflammation with no demyelination in the central nervous system.
Chemical Information
-
CAS No. 163158-19-8
-
Appearance Solid
-
Masse moléculaire 2591.99
-
Formule C120H179N35O28S
-
Color White to off-white
-
Sequence Shortening
MEVGWYRPPFSRVVHLYRNGK
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Solvant et solubilité
In Vitro:
H2O : ≥ 50 mg/mL (19.29 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocole
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
-
Fiche technique (271 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Albouz-Abo S, et al. A conformational study of the human and rat encephalitogenic myelin oligodendrocyte glycoprotein peptides 35-55. European journal of biochemistry. 1997 May 15;246(1):59-70. [Content Brief]
[2]. Capper EN, et al. MOG-induced EAE model of optic nerve inflammation compared to MS, MOGAD and NMOSD related subtypes of human optic neuritis. Journal of neuroinflammation. 2025 Apr 07;22(1):102. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.3858 mL | 1.9290 mL | 3.8580 mL | 9.6451 mL |
| 5 mM | 0.0772 mL | 0.3858 mL | 0.7716 mL | 1.9290 mL | |
| 10 mM | 0.0386 mL | 0.1929 mL | 0.3858 mL | 0.9645 mL | |
| 15 mM | 0.0257 mL | 0.1286 mL | 0.2572 mL | 0.6430 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
MOG (35-55), human Related Classifications
HY-P2459 Related Classifications
Powered by Bioz
Keywords
- MOG (35-55), human
- 163158-19-8
- Others
- NOD/Lt mice
- neuromyelitis optica spectrum disorder
- experimental autoimmune encephalomyelitis
- mice
- central nervous system inflammation
- optic neuritis
- myelin oligodendrocyte glycoprotein
- multiple sclerosis
- C57BL/6 mice
- myelin oligodendrocyte glycoprotein antibody-associated disease
- Inhibitor
- inhibitor
- inhibit